Alessandro Serretti

TL;DR: Clinicians should purposely investigate this side effect both before and after the prescription of a given antipsychotics and should be aware of strategies to manage antipsychotic-related SD.

TL;DR: In this article, a review discusses possible strategies to facilitate the identification of genetic biomarkers with clinical usefulness in guiding antidepressant treatments, including analysis methods for the study of the polygenic/omnigenic nature of antidepressant response, prioritization of polymorphisms on the basis of functional considerations, the incorporation of clinical-demographic predictors in pharmacogenetic studies (e.g. mixed polygenic and clinical risk scores), the application of methodological improvements to the design of future studies in order to maximize the comparability of results and improve power.

TL;DR: This study investigated the role of a set of genes involved in different pathways in the treatment outcome of major depressive disorder (MDD) and bipolar disorder (BD) after naturalistic pharmacological treatment to support the involvement of some candidate genes in the outcomes of treatments for mood disorders, as well as in BD risk and other disease features.

TL;DR: Although the analysis of pooled samples has positive results for the association between SORL1 and AD, there is substantial heterogeneity across studies, and further examination into SorL1 SNPs and the population is necessary to determine the role of SORl1 in LOAD.

TL;DR: The hypothesis that the molecular pathways involved with the direct targets of lithium, hold significantly more genetic variations associated with Bipolar Disorder is tested, which points out to a possible involvement of microtubule-related mechanics.